Protagonist Therapeutics (PTGX) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart

Protagonist Therapeutics Revenue Highlights

Latest Revenue (Y)

$60.00M

Latest Revenue (Q)

$4.67M

Main Segment (Y)

License and Collaboration Agreement

Main Geography (Y)

License and Collaboration Agreement

Protagonist Therapeutics Revenue by Period

Protagonist Therapeutics Revenue by Year

Date	Revenue	Change
2023-12-31	$60.00M	125.73%
2022-12-31	$26.58M	-2.84%
2021-12-31	$27.36M	-4.44%
2020-12-31	$28.63M	12293.07%
2019-12-31	$231.00K	-99.25%
2018-12-31	$30.93M	54.14%
2017-12-31	$20.06M	100.00%
2016-12-31	-	100.00%
2015-12-31	-	100.00%
2014-12-31	-	-

Protagonist Therapeutics generated $60.00M in revenue during NA 2023, up 125.73% compared to the previous quarter, and up 194.02% compared to the same period a year ago.

Protagonist Therapeutics Revenue by Quarter

Date	Revenue	Change
2024-09-30	$4.67M	12.19%
2024-06-30	$4.17M	-98.37%
2024-03-31	$254.95M	324.92%
2023-12-31	$60.00M	100.00%
2023-09-30	-	100.00%
2023-06-30	-	100.00%
2023-03-31	-	100.00%
2022-12-31	-	100.00%
2022-09-30	-	-100.00%
2022-06-30	$859.00K	-96.66%
2022-03-31	$25.72M	198.50%
2021-12-31	$8.62M	-16.23%
2021-09-30	$10.29M	354.13%
2021-06-30	$2.27M	-63.40%
2021-03-31	$6.19M	9.54%
2020-12-31	$5.65M	-56.92%
2020-09-30	$13.11M	110.94%
2020-06-30	$6.22M	70.47%
2020-03-31	$3.65M	34.13%
2019-12-31	$2.72M	-34.34%
2019-09-30	$4.14M	-150.57%
2019-06-30	$-8.19M	-624.94%
2019-03-31	$1.56M	-33.70%
2018-12-31	$2.35M	-61.53%
2018-09-30	$6.12M	-47.60%
2018-06-30	$11.67M	8.28%
2018-03-31	$10.78M	-4.44%
2017-12-31	$11.28M	28.48%
2017-09-30	$8.78M	100.00%
2017-06-30	-	100.00%
2017-03-31	-	100.00%
2016-12-31	-	100.00%
2016-09-30	-	100.00%
2016-06-30	-	100.00%
2016-03-31	-	100.00%
2015-12-31	-	100.00%
2015-09-30	-	100.00%
2015-06-30	-	100.00%
2015-03-31	-	-

Protagonist Therapeutics generated $4.67M in revenue during Q3 2024, up 12.19% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Protagonist Therapeutics Revenue Breakdown

Protagonist Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 21	Dec 20	Dec 19
License and Collaboration Agreement	$18.60M	-	-
License And Collaborative Revenue	-	$28.60M	$200.00K
Financial Service Other	-	$1.50M	-

Protagonist Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 21: License and Collaboration Agreement (100.00%).

Quarterly Revenue by Product

Product/Service	Sep 24	Mar 24	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Mar 19	Sep 18	Jun 18	Mar 18
Development Services	$9.70M	$900.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License and Collaboration Agreement	-	-	$900.00K	$25.70M	$10.60M	-	-	-	-	-	-	-	-	-	-	-
License And Service	-	-	-	-	-	$8.00M	-	-	-	-	-	-	-	-	-	-
License And Collaborative Revenue	-	-	-	-	-	-	$95.80M	$96.30M	$6.60M	$99.40M	$113.90M	$113.60M	$1.60M	$6.10M	$11.67M	$10.78M
Financial Service Other	-	-	-	-	-	-	$200.00K	$600.00K	$500.00K	$500.00K	$500.00K	-	-	-	-	-

Protagonist Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Development Services (100.00%).

Protagonist Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 21	Dec 20	Dec 19
License and Collaboration Agreement	$18.60M	-	-
Financial Service Other	-	$1.50M	-
License And Collaborative Revenue	-	$28.60M	$200.00K

Protagonist Therapeutics's latest annual revenue breakdown by geography, as of Dec 21: License and Collaboration Agreement (100.00%).

Quarterly Revenue by Country

Country	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Mar 19	Sep 18	Jun 18	Mar 18
License and Collaboration Agreement	$900.00K	$25.70M	$10.60M	-	-	-	-	-	-	-	-	-	-	-
License And Service	-	-	-	$8.00M	-	-	-	-	-	-	-	-	-	-
License And Collaborative Revenue	-	-	-	-	$95.80M	$96.30M	$6.60M	$99.40M	$113.90M	$113.60M	$1.60M	$6.10M	$11.67M	$10.78M
Financial Service Other	-	-	-	-	$200.00K	$600.00K	$500.00K	$500.00K	$500.00K	-	-	-	-	-

Protagonist Therapeutics's latest quarterly revenue breakdown by geography, as of Jun 22: License and Collaboration Agreement (100.00%).

Protagonist Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
ARVN	Arvinas	$78.50M	$102.40M
PTGX	Protagonist Therapeutics	$60.00M	$4.67M
MRUS	Merus	$43.95M	$11.77M
RLAY	Relay Therapeutics	$25.55M	-
IDYA	IDEAYA Biosciences	$23.39M	-
HOOK	HOOKIPA Pharma	$20.13M	-
RVMD	Revolution Medicines	$11.58M	-
RNA	Avidity Biosciences	$9.56M	$2.04M
STOK	Stoke Therapeutics	$8.78M	$4.89M
PLRX	Pliant Therapeutics	$1.58M	-
BDTX	Black Diamond Therapeutics	-	-
XFOR	X4 Pharmaceuticals	-	$560.00K
DAWN	Day One Biopharmaceuticals	-	$20.07M
ABOS	Acumen Pharmaceuticals	-	-
VRNA	Verona Pharma	-	$5.62M
REPL	Replimune Group	-	-
KURA	Kura Oncology	-	-
SNDX	Syndax Pharmaceuticals	-	$12.50M
TERN	Terns Pharmaceuticals	-	-
VTYX	Ventyx Biosciences	-	-
AKRO	Akero Therapeutics	-	-

PTGX Revenue FAQ

What is Protagonist Therapeutics’s yearly revenue?

Protagonist Therapeutics's yearly revenue for 2023 was $60M, representing an increase of 125.73% compared to 2022. The company's yearly revenue for 2022 was $26.58M, representing a decrease of -2.84% compared to 2021. PTGX's yearly revenue for 2021 was $27.36M, representing a decrease of -4.44% compared to 2020.

What is Protagonist Therapeutics’s quarterly revenue?

Protagonist Therapeutics's quarterly revenue for Q3 2024 was $4.68M, a 12.19% increase from the previous quarter (Q2 2024), and a 0% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $4.17M, a -98.37% decrease from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). PTGX's quarterly revenue for Q1 2024 was $254.95M, a 324.92% increase from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023).

What is Protagonist Therapeutics’s revenue growth rate?

Protagonist Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 119.32%, and for the last 5 years (2019-2023) was 25874.03%.

What are Protagonist Therapeutics’s revenue streams?

Protagonist Therapeutics's revenue streams in c 21 are License and Collaboration Agreement

What is Protagonist Therapeutics’s main source of revenue?

For the fiscal year ending Dec 21, the largest source of revenue of Protagonist Therapeutics was License and Collaboration Agreement. This segment made a revenue of $18.6M, representing 100.00% of the company's total revenue.